Global Life Sciences Cluster Report 2011 - Jones Lang LaSalle

2.0%
R&D expenditure
(% of GDP, 2007)
Established cluster
France
3,496
Researchers in
R&D (per million
people, 2007)
France is one of the leaders in the life sciences industry, thanks in large
part to the size of its market. It is first in Europe in terms of medicine
production by volume and among the main global pharmaceutical exporters.
Overview
23.0%
High technology
exports (% overall
exports, 2009)
70 EMEA | Jones Lang LaSalle
11.7%
Total health
expenditure
(% of GDP, 2009)
France’s life sciences industry produces yearly revenue
of about €47 billion ($66.5 billion) 1 and reinvests more than
€1 billion ($1.4 billion) 1 each year. The country is acknowledged
for the quality of its research and for its history of therapeutic
innovation and it benefits from the best health system in the
world, according to the OECD.
The French landscape is clearly dominated by the Paris
region due to its strategic location and its high education level,
important concentration of prestigious hospitals and high-tech
research. Consequently, Paris and its closest suburbs host
most of the largest pharmaceutical headquarters. Even
though there are no easily identifiable submarket clusters,
17
World economic
forum’s innovation
rank (out of 142)
it is nonetheless possible to spot some higher concentrations
of laboratories in the first western inner suburb which include
Roche, Ipsen and Pierre Fabre at Boulogne, Servier at
Suresnes, Bayer Schering at Puteaux, AstraZenexa,
Bristol-Meyers Squibb (BMS) at Rueil Malmaison, and to
a lesser extent in the south outer suburb.
The ambitious plan for “Grand Paris”, a major urban planning
project to reinforce the position of Paris as a leading city on the
international scene, also involves a dedicated cluster located
in the Villejuif/Evry submarket. This cluster will specialize in
healthcare and life sciences, capitalizing on high-level research
institutes specializing in a variety of treatment arenas.
Tof C